Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

Diagnostics & Research is Zen Rated B and is the 53rd ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
ILMN	ILLUMINA INC	$11.40B	$72.00	$131.08	82.06%	Buy	12	2.33%	N/A	39.61%	14.91%
QGEN	QIAGEN NV	$9.00B	$40.48	$48.25	19.19%	Buy	4	5.30%	92.36%	18.01%	11.29%
WAT	WATERS CORP	$18.79B	$316.23	$396.00	25.23%	Buy	12	5.46%	15.21%	52.28%	20.99%
TMO	THERMO FISHER SCIENTIFIC INC	$159.15B	$421.85	$633.85	50.25%	Buy	13	4.68%	25.05%	22.48%	11.45%
LH	LABCORP HOLDINGS INC	$17.76B	$212.22	$274.64	29.41%	Strong Buy	11	5.73%	29.55%	22.98%	10.07%
MTD	METTLER TOLEDO INTERNATIONAL INC	$20.29B	$970.15	$1.36k	40.58%	Buy	5	3.62%	8.66%	-910.41%	35.65%
CDNA	CAREDX INC	$938.91M	$16.94	$30.00	77.10%	Buy	5	11.14%	N/A	-1.90%	-1.47%
A	AGILENT TECHNOLOGIES INC	$28.58B	$100.26	$141.86	41.49%	Buy	7	4.56%	17.77%	31.32%	15.84%
RVTY	REVVITY INC	$10.79B	$89.77	$132.00	47.04%	Strong Buy	8	4.83%	58.17%	9.69%	5.99%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$5.25B	$102.67	$188.67	83.76%	Hold	12	-0.27%	614.29%	16.62%	7.64%
DHR	DANAHER CORP	$132.19B	$184.96	$275.00	48.68%	Strong Buy	15	3.96%	27.00%	13.80%	8.82%
DGX	QUEST DIAGNOSTICS INC	$17.96B	$161.86	$181.54	12.16%	Buy	13	5.49%	13.19%	20.43%	8.57%
IQV	IQVIA HOLDINGS INC	$24.87B	$141.22	$237.00	67.82%	Strong Buy	16	4.93%	21.77%	43.86%	9.89%
IDXX	IDEXX LABORATORIES INC	$33.07B	$406.65	$505.83	24.39%	Buy	6	7.20%	12.16%	87.53%	42.40%
OPK	OPKO HEALTH INC	$920.02M	$1.37	$2.63	91.61%	Buy	2	4.02%	N/A	0.98%	0.61%
MYGN	MYRIAD GENETICS INC	$675.69M	$7.40	$18.35	147.97%	Buy	10	5.05%	N/A	-0.52%	-0.36%
CSTL	CASTLE BIOSCIENCES INC	$602.79M	$21.14	$39.60	87.32%	Strong Buy	5	-2.78%	N/A	-8.26%	-7.09%
NTRA	NATERA INC	$19.23B	$142.23	$192.17	35.11%	Strong Buy	12	15.55%	N/A	3.22%	2.32%
MEDP	MEDPACE HOLDINGS INC	$8.80B	$288.99	$341.60	18.20%	Hold	5	6.79%	4.62%	59.62%	23.43%
FONR	FONAR CORP	$80.09M	$12.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$2.06B	$34.56	$53.17	53.84%	Buy	6	17.44%	N/A	-13.21%	-9.90%
FLGT	FULGENT GENETICS INC	$552.46M	$17.92	$16.00	-10.71%	Hold	1	10.03%	N/A	-4.98%	-4.62%
MYNZ	MAINZ BIOMED NV	$7.12M	$3.07	$14.00	356.03%	Strong Buy	1	N/A	N/A	-352.90%	-161.19%
XGN	EXAGEN INC	$79.29M	$4.43	$7.50	69.30%	Strong Buy	2	15.38%	N/A	-43.15%	-9.21%
SHC	SOTERA HEALTH CO	$2.93B	$10.32	$16.33	58.27%	Strong Buy	3	4.50%	121.74%	N/A	N/A
NEO	NEOGENOMICS INC	$1.23B	$9.58	$17.80	85.80%	Strong Buy	5	11.91%	N/A	2.18%	1.20%
ICLR	ICON PLC	$11.08B	$137.23	$213.10	55.29%	Buy	10	3.82%	20.61%	15.66%	8.84%
BDSX	BIODESIX INC	$72.99M	$0.50	N/A	N/A	N/A	N/A	30.04%	N/A	-97.90%	-21.02%
ADVB	ADVANCED BIOMED INC	$36.14M	$1.67	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STIM	NEURONETICS INC	$255.36M	$3.88	$7.50	93.30%	Strong Buy	2	99.83%	N/A	-66.51%	-13.08%
OCX	ONCOCYTE CORP	$82.37M	$2.88	$4.42	53.37%	Buy	3	N/A	N/A	N/A	-69.30%
DRIO	DARIOHEALTH CORP	$30.34M	$0.73	$2.00	173.97%	Strong Buy	1	18.66%	N/A	N/A	N/A
GRAL	GRAIL INC	$895.51M	$26.42	$26.00	-1.59%	Buy	2	13.37%	N/A	-11.21%	-9.41%
GH	GUARDANT HEALTH INC	$5.26B	$42.61	$53.07	24.55%	Strong Buy	14	19.89%	N/A	N/A	-17.25%
EXAS	EXACT SCIENCES CORP	$8.01B	$43.10	$68.95	59.97%	Strong Buy	19	12.16%	N/A	11.10%	4.50%
APDN	APPLIED DNA SCIENCES INC	$894.05k	$0.81	N/A	N/A	N/A	N/A	-9.46%	N/A	N/A	N/A
LAB	STANDARD BIOTOOLS INC	$450.99M	$1.19	$2.50	110.08%	Strong Buy	1	-3.00%	N/A	-13.26%	-10.21%
PSNL	PERSONALIS INC	$278.91M	$3.16	$8.00	153.16%	Strong Buy	4	22.87%	N/A	-4.35%	-3.27%
RDNT	RADNET INC	$3.51B	$47.36	$69.75	47.28%	Strong Buy	4	5.34%	866.75%	5.63%	1.55%
NOTV	INOTIV INC	$54.53M	$1.61	N/A	N/A	N/A	N/A	5.50%	N/A	-2.59%	-0.57%
SERA	SERA PROGNOSTICS INC	$127.68M	$3.39	N/A	N/A	N/A	N/A	1,133.77%	N/A	N/A	N/A
ACRS	ACLARIS THERAPEUTICS INC	$121.95M	$1.13	$11.67	932.48%	Strong Buy	6	13.26%	N/A	-59.66%	-42.12%
ISPC	ISPECIMEN INC	$2.95M	$1.18	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NEOG	NEOGEN CORP	$1.02B	$4.69	$9.75	107.89%	Buy	2	0.33%	N/A	4.00%	2.63%
PRPO	PRECIPIO INC	$7.88M	$5.24	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRIB	TRINITY BIOTECH PLC	$4.28M	$0.56	N/A	N/A	N/A	N/A	15.85%	N/A	N/A	-77.09%
STRR	STAR EQUITY HOLDINGS INC	$5.77M	$1.80	N/A	N/A	N/A	N/A	N/A	N/A	-3.19%	-2.08%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$9.07M	$0.50	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BNR	BURNING ROCK BIOTECH LTD	$29.68M	$2.88	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PMAX	POWELL MAX LTD	$4.70M	$0.32	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
XWEL	XWELL INC	$3.95M	$0.75	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$1.89M	$3.36	$50.00	1,388.10%	Buy	1	N/A	N/A	-337.72%	-194.21%
MMA	MIXED MARTIAL ARTS GROUP LTD	$9.68M	$0.94	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRPH	PROPHASE LABS INC	$12.98M	$0.31	N/A	N/A	N/A	N/A	109.24%	N/A	N/A	N/A
PRE	PRENETICS GLOBAL LTD	$52.56M	$4.30	$9.00	109.30%	Strong Buy	1	N/A	N/A	-14.50%	-10.99%
MDXH	MDXHEALTH SA	$7.92M	$1.60	$6.00	275.00%	Strong Buy	1	20.55%	N/A	-71.14%	-6.71%
CHEK	CHECK-CAP LTD	$3.80M	$0.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$46.15M	$0.48	$3.75	684.52%	Strong Buy	2	N/A	N/A	N/A	N/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #1 top diagnostic & research stock out of 58 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: C, Safety: B, Financials: B, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 16, which is -11 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "A".

ILMN passed 5 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -40.12% over the past year, underperforming other diagnostic & research stocks by -10 percentage points.

Illumina has an average 1 year price target of $131.08, an upside of 82.06% from Illumina's current stock price of $72.00.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Illumina, 33.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the #2 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: B.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 23, which is -4 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "B".

QGEN passed 9 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock lose -1.8% over the past year, overperforming other diagnostic & research stocks by 28 percentage points.

Qiagen Nv has an average 1 year price target of $48.25, an upside of 19.19% from Qiagen Nv's current stock price of $40.48.

Qiagen Nv stock has a consensus Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Qiagen Nv, 25% have issued a Strong Buy rating, 0% have issued a Buy, 75% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Waters (NYSE:WAT)

Waters (NYSE:WAT) is the #3 top diagnostic & research stock out of 58 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Waters (NYSE:WAT) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: A, and AI: B.

Waters (NYSE:WAT) has a Due Diligence Score of 36, which is 9 points higher than the diagnostic & research industry average of 27.

WAT passed 12 out of 33 due diligence checks and has average fundamentals. Waters has seen its stock return 5.68% over the past year, overperforming other diagnostic & research stocks by 36 percentage points.

Waters has an average 1 year price target of $396.00, an upside of 25.23% from Waters's current stock price of $316.23.

Waters stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Waters, 16.67% have issued a Strong Buy rating, 16.67% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 5 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.42%, which is 1 percentage points higher than the diagnostic & research industry average of 0.64%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.6% indicates that its dividend yield is sustainable for the long-term.

2. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.72%, which is the same as the diagnostic & research industry average of 0.64%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 21.9% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.68%, which is the same as the diagnostic & research industry average of 0.64%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 24.3% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -2.18% in the last day, and down -6.06% over the last week. Medpace Holdings was the among the top losers in the diagnostics & research industry, dropping -2.46% yesterday.

Medpace Holdings shares are trading lower. The company reported Q1 financial results.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 40 points higher than the diagnostic & research industry average of 17. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -53.94% in the past year. It has underperformed other stocks in the diagnostic & research industry by -24 percentage points.

2. Charles River Laboratories International (NYSE:CRL)

Charles River Laboratories International (NYSE:CRL) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Charles River Laboratories International has a valuation score of 29, which is 12 points higher than the diagnostic & research industry average of 17. It passed 2 out of 7 valuation due diligence checks.

Charles River Laboratories International's stock has dropped -55.85% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Agilent Technologies has a valuation score of 29, which is 12 points higher than the diagnostic & research industry average of 17. It passed 2 out of 7 valuation due diligence checks.

Agilent Technologies's stock has dropped -25.13% in the past year. It has overperformed other stocks in the diagnostic & research industry by 5 percentage points.

Are diagnostic & research stocks a good buy now?

51.22% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 41.48% over the next year.

2.27% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 18.18% of diagnostic & research stocks are rated B (Buy), 68.18% are rated C (Hold), 11.36% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 35.03x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.